profit from every $100 of sales.
$0$100
GT Biopharma
$3.72-3.12% today
-83.0% in 1 year
1-year low $3.721-year high $27.62
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What GT Biopharma sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$28.4 million of profit last year.
SalesProfit
GT Biopharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| GT Biopharma | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads GT Biopharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -21 | -14 | -14 | -12 | |
| -21 | -7 | -13 | -28 | |
| -21 | -8 | -13 | -28 | |
| -19.46 | -5.64 | -6.94 | -6.68 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 17 | 14 | 4 | 8 |
| Cash | 6 | 1 | 4 | 7 |
| Total debt | 0 | 0 | 0 | – |
| Total liabilities | 5 | 7 | 6 | 2 |
| 12 | 7 | -2 | 6 | |
| 1 | 1 | 2 | 6 | |
| -138.5% | -77.4% | – | -385.3% | |
| -178.0% | -101.6% | 788.1% | -490.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -15 | -9 | -13 | -13 | |
| – | – | – | – | |
| -15 | -9 | -13 | -13 | |
| Dividends paid | – | – | 0 | 0 |
| 0 | 0 | – | – | |
| 8 | 2 | 0 | 0 |
Valuation
- –
- –
- –
- 0.4×
- –
- –
- 0.1×
- -168.4%
- -369.8%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -214.7%
- -48.5%
- -898.4%
- -349.8%
- -214.7%
- –
Growth
- –
- –
- −0.1%
- –
- −33.5%
Financial health
- -0.2×
- 0.00
- 0.0%
- -97.8×
- 3.50
- 3.50
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 883
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.11 | -0.08 | −37.5% |
| Mar 2, 2026 | -2.22 | -0.22 | −909.1% |
| Nov 14, 2025 | -0.83 | -0.38 | −118.4% |
| Aug 14, 2025 | -0.55 | -0.68 | +19.1% |
| May 15, 2025 | -0.76 | -0.64 | −18.8% |
| Feb 21, 2025 | -1.66 | -1.55 | −7.1% |
| Nov 14, 2024 | -1.53 | -2.70 | +43.3% |
| Aug 14, 2024 | -2.24 | -2.70 | +17.0% |
News
COSCIENS Biopharma Inc. GAAP EPS of -$3.45, revenue of $2.5MSeeking Alpha · Nov 14, 2026The big winners of the tech wreck are biopharma stocksMarketWatch · Oct 30, 2026Ligand Pharma a new Outperform at Barclays on biopharma royalty aggregationSeeking Alpha · Sep 25, 2026Chinese biopharma stocks jump as U.S. weighs keeping door open to drug dealsCNBC · Sep 21, 2026Moderna’s cancer-vaccine breakthrough drives broad biopharma stock rallyMarketWatch · Aug 19, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/7Passes 3 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
45No pass
Benjamin Graham
79Pass
Philip Fisher
37No pass
Peter Lynch
60Pass
Joel Greenblatt
100Pass
Charlie Munger
32No pass
Terry Smith
26No pass
Questions about GT Biopharma
Is GT Biopharma a good stock to buy?
A business with weak numbers that is not profitable yet. 3 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the GT Biopharma AI analysis
What does GT Biopharma do?
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It is in Biotechnology.
Does GT Biopharma pay a dividend?
Yes. In 2025 it paid out $229,000 in dividends.
Is GT Biopharma stock halal?
No. GT Biopharma does not pass our halal screen: its cash and confirmed interest-bearing investments are 89% of its market value, at or above the 33% limit. How we check
How has GT Biopharma stock done over the past year?
Down 83.0% over the past twelve months, to $3.72. It traded between $3.72 and $27.62 and is 86.5% below its high.
Who are GT Biopharma's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with GT Biopharma's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.